CR20160002A - Formulación estable líquida de etelcalcetide (amg 461) - Google Patents

Formulación estable líquida de etelcalcetide (amg 461)

Info

Publication number
CR20160002A
CR20160002A CR20160002A CR20160002A CR20160002A CR 20160002 A CR20160002 A CR 20160002A CR 20160002 A CR20160002 A CR 20160002A CR 20160002 A CR20160002 A CR 20160002A CR 20160002 A CR20160002 A CR 20160002A
Authority
CR
Costa Rica
Prior art keywords
etelcalcetide
amg
stable formulation
formulation liquid
liquid
Prior art date
Application number
CR20160002A
Other languages
English (en)
Inventor
Dereck Maclean
Qun Yin
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51213030&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20160002(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of CR20160002A publication Critical patent/CR20160002A/es

Links

Classifications

    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F04—POSITIVE - DISPLACEMENT MACHINES FOR LIQUIDS; PUMPS FOR LIQUIDS OR ELASTIC FLUIDS
    • F04D—NON-POSITIVE-DISPLACEMENT PUMPS
    • F04D25/00—Pumping installations or systems
    • F04D25/02—Units comprising pumps and their driving means
    • F04D25/06—Units comprising pumps and their driving means the pump being electrically driven
    • F04D25/0606—Units comprising pumps and their driving means the pump being electrically driven the electric motor being specially adapted for integration in the pump
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F01—MACHINES OR ENGINES IN GENERAL; ENGINE PLANTS IN GENERAL; STEAM ENGINES
    • F01D—NON-POSITIVE DISPLACEMENT MACHINES OR ENGINES, e.g. STEAM TURBINES
    • F01D15/00—Adaptations of machines or engines for special use; Combinations of engines with devices driven thereby
    • F01D15/10—Adaptations for driving, or combinations with, electric generators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Mechanical Engineering (AREA)
  • General Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se proporcionan una formulación líquida que comprende un agonista péptido del receptor (etelcalcetide, también conocido como AMG 416) que detecta calcio y un método para preparar y usar la formulación
CR20160002A 2013-06-28 2014-06-27 Formulación estable líquida de etelcalcetide (amg 461) CR20160002A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361840618P 2013-06-28 2013-06-28
PCT/US2014/044622 WO2014210489A1 (en) 2013-06-28 2014-06-27 Stable liquid formulation of amg 416 (velcalcetide)

Publications (1)

Publication Number Publication Date
CR20160002A true CR20160002A (es) 2018-02-13

Family

ID=51213030

Family Applications (2)

Application Number Title Priority Date Filing Date
CR20160002A CR20160002A (es) 2013-06-28 2014-06-27 Formulación estable líquida de etelcalcetide (amg 461)
CR20160061A CR20160061A (es) 2013-06-28 2014-06-27 Formulación estable líquida de etelcalcetide (amg 461)

Family Applications After (1)

Application Number Title Priority Date Filing Date
CR20160061A CR20160061A (es) 2013-06-28 2014-06-27 Formulación estable líquida de etelcalcetide (amg 461)

Country Status (38)

Country Link
US (4) US9820938B2 (es)
EP (3) EP3246017B1 (es)
JP (1) JP6027708B2 (es)
KR (1) KR102231957B1 (es)
CN (2) CN105764487A (es)
AP (1) AP2015008936A0 (es)
AR (1) AR096773A1 (es)
AU (1) AU2014302122B2 (es)
CA (1) CA2916222C (es)
CL (1) CL2015003738A1 (es)
CR (2) CR20160002A (es)
CY (1) CY1120811T1 (es)
DK (1) DK3013318T3 (es)
EA (1) EA030220B1 (es)
ES (1) ES2633989T3 (es)
HR (1) HRP20171092T1 (es)
HU (1) HUE034209T2 (es)
IL (1) IL243210B (es)
JO (1) JO3817B1 (es)
LT (1) LT3013318T (es)
MA (1) MA38724B1 (es)
ME (1) ME02818B (es)
MX (1) MX2015017952A (es)
MY (1) MY180276A (es)
PE (2) PE20160549A1 (es)
PH (1) PH12015502816B1 (es)
PL (1) PL3013318T3 (es)
PT (1) PT3013318T (es)
RS (1) RS56238B1 (es)
SG (1) SG11201510647TA (es)
SI (1) SI3013318T1 (es)
SM (1) SMT201700401T1 (es)
TN (1) TN2015000569A1 (es)
TW (1) TWI635874B (es)
UA (1) UA115373C2 (es)
UY (1) UY35636A (es)
WO (1) WO2014210489A1 (es)
ZA (1) ZA201600238B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2916222C (en) 2013-06-28 2021-05-18 Amgen Inc. Stable liquid formulation of amg 416 (etelcalcetide)
PL3126373T3 (pl) 2014-04-03 2020-07-27 Amgen Inc. Sposób wytwarzania amg 416
US10858389B2 (en) 2015-03-26 2020-12-08 Amgen Inc. Solution phase method for preparing etelcalcetide
CN106137979A (zh) * 2015-03-31 2016-11-23 深圳翰宇药业股份有限公司 一种冻干粉针剂及其制备方法
CN106928320B (zh) * 2015-12-31 2021-01-15 深圳翰宇药业股份有限公司 一种合成Etelcalcetide的方法
CN106928321B (zh) * 2015-12-31 2019-07-26 深圳翰宇药业股份有限公司 一种合成Etelcalcetide的方法
CN110054662B (zh) * 2018-01-18 2021-03-02 成都圣诺生物制药有限公司 一种固相合成Etelcalcetide的方法
EP4149507A1 (en) 2020-05-15 2023-03-22 Amgen Inc. Methods of treating left ventricle hypertrophy
CN111925415A (zh) * 2020-08-10 2020-11-13 海南中和药业股份有限公司 一种维拉卡肽杂质的制备方法
WO2022034545A1 (en) * 2020-08-14 2022-02-17 Aurobindo Pharma Limited Etelcalcetide formulations for parenteral use
US20240207354A1 (en) 2021-05-06 2024-06-27 Amgen Inc. Etelcalcetide formulations

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2270154A1 (en) 1996-10-25 1998-04-30 The Government Of The United States Of America As Represented By The Sec Retary, Department Of Health And Human Services Methods and compositions for inhibiting inflammation and angiogenesis comprising a mammalian cd97 alpha subunit
AT409081B (de) 2000-02-16 2002-05-27 Gebro Pharma Gmbh Stabile, nasal, oral oder sublingual anwendbare pharmazeutische zubereitung
BRPI0410972C1 (pt) * 2003-06-03 2021-05-25 Novo Nordisk As método para aumentar a vida de armazenagem de uma composição farmacêutica, composição farmacêutica, e, método para tratamento de hiperglicemia
PL1633390T3 (pl) 2003-06-03 2012-06-29 Novo Nordisk As Stabilizowane kompozycje farmaceutyczne peptydu glp-1
US7265092B2 (en) 2004-09-30 2007-09-04 Kai Pharmaceuticals, Inc. Pharmaceutical formulation
CN101668421B (zh) 2006-11-16 2014-05-21 凯制药公司 用于治疗甲状旁腺功能亢进和高钙血症的聚阳离子钙调节肽
WO2008089491A2 (en) 2007-01-19 2008-07-24 Kai Pharmaceuticals, Inc. Modifications of peptide compositions to increase stability and delivery efficiency
EP2264138B2 (en) 2009-06-19 2023-03-08 The Procter & Gamble Company Liquid hand dishwashing detergent composition
ES2729051T3 (es) 2009-07-29 2019-10-30 Kai Pharmaceuticals Inc Agentes terapéuticos para reducir los niveles de hormona paratiroidea
EP2399604A1 (en) 2010-06-25 2011-12-28 F. Hoffmann-La Roche AG Novel antibody formulation
WO2012075375A1 (en) * 2010-12-02 2012-06-07 Lanco Biosciences, Inc. Delivery of parathyroid hormones by microinjection systems
WO2012170955A1 (en) 2011-06-08 2012-12-13 Kai Pharmaceuticals, Inc. Therapeutic agents for regulating serum phosphorus
AU2012335009B2 (en) 2011-11-10 2017-08-31 Kai Pharmaceuticals, Inc. Calcimimetics and methods for their use
CA2916222C (en) 2013-06-28 2021-05-18 Amgen Inc. Stable liquid formulation of amg 416 (etelcalcetide)
PL3126373T3 (pl) * 2014-04-03 2020-07-27 Amgen Inc. Sposób wytwarzania amg 416

Also Published As

Publication number Publication date
CA2916222A1 (en) 2014-12-31
MA38724B1 (fr) 2017-11-30
JP6027708B2 (ja) 2016-11-16
SMT201700401T1 (it) 2017-09-07
HUE034209T2 (en) 2018-02-28
KR102231957B1 (ko) 2021-03-25
PH12015502816A1 (en) 2016-03-21
PE20160549A1 (es) 2016-06-15
EP3013318B1 (en) 2017-04-19
UY35636A (es) 2015-01-30
RS56238B1 (sr) 2017-11-30
EP3878433A1 (en) 2021-09-15
IL243210A0 (en) 2016-02-29
ME02818B (me) 2018-01-20
SI3013318T1 (sl) 2017-11-30
WO2014210489A1 (en) 2014-12-31
MY180276A (en) 2020-11-26
BR112015032615A2 (pt) 2017-07-25
JP2016523916A (ja) 2016-08-12
US9820938B2 (en) 2017-11-21
EP3246017B1 (en) 2021-03-24
PH12015502816B1 (en) 2016-03-21
EP3013318A1 (en) 2016-05-04
US20160220486A1 (en) 2016-08-04
PE20210413A1 (es) 2021-03-04
AP2015008936A0 (en) 2015-12-31
US10344765B2 (en) 2019-07-09
US20220042515A1 (en) 2022-02-10
TWI635874B (zh) 2018-09-21
JO3817B1 (ar) 2021-01-31
MA38724A1 (fr) 2017-03-31
PT3013318T (pt) 2017-07-24
CR20160061A (es) 2016-09-28
CA2916222C (en) 2021-05-18
UA115373C2 (uk) 2017-10-25
CL2015003738A1 (es) 2016-12-09
US11162500B2 (en) 2021-11-02
TN2015000569A1 (en) 2017-04-06
LT3013318T (lt) 2017-09-11
KR20160043954A (ko) 2016-04-22
ES2633989T3 (es) 2017-09-26
AU2014302122A1 (en) 2016-01-21
AU2014302122B2 (en) 2018-12-06
HRP20171092T1 (hr) 2017-10-06
CN105764487A (zh) 2016-07-13
PL3013318T3 (pl) 2018-03-30
ZA201600238B (en) 2017-05-31
CY1120811T1 (el) 2019-12-11
TW201542239A (zh) 2015-11-16
NZ715403A (en) 2020-10-30
AR096773A1 (es) 2016-02-03
HK1222557A1 (en) 2017-07-07
US20180080452A1 (en) 2018-03-22
US11959486B2 (en) 2024-04-16
MX2015017952A (es) 2016-10-28
EA201690099A1 (ru) 2016-06-30
IL243210B (en) 2020-02-27
EA030220B1 (ru) 2018-07-31
CN114376970A (zh) 2022-04-22
EP3246017A1 (en) 2017-11-22
DK3013318T3 (en) 2017-08-07
SG11201510647TA (en) 2016-01-28
US20190285074A1 (en) 2019-09-19

Similar Documents

Publication Publication Date Title
CR20160002A (es) Formulación estable líquida de etelcalcetide (amg 461)
ECSP17016797A (es) Indazoles sustituidos con benzilo como inhibidores de bub1
EA201891209A1 (ru) Модуляторы хемокиновых рецепторов
MX2015011514A (es) Compuestos de heteroarilo y sus usos.
CL2015002123A1 (es) Moduladores de receptores nmda de espiro-lactama y sus usos
CR20150524A (es) Compuestos de heteroarilo y sus usos
UY35500A (es) Indazoles sustituidos con heteroarilo
UY34792A (es) ?método de uso de profungicidas de uk-2a para control de la roya de soja?.
UY34804A (es) Inhibidores del nampt
AR101742A1 (es) Agonista del receptor de calcitonina y amilina
CR20140512A (es) Dispositivos y metodos para la fabricación de aditivos de componentes de implante
UY34566A (es) 1,4?dihidropirimidinas 4,4?disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b
DK3352625T3 (da) Reorganiserbar liggestol til flere formål, flere anvendelser
UY34767A (es) Inhibidores cíclicos del enlace éter de dgat1
UY34730A (es) Formulaciones farmacéuticas que comprenden antagonistas de ccr3
ECSP16012582A (es) Compuestos heterocíclicos y métodos de uso
UY35750A (es) Moduladores octahidro-ciclopenta[c] pirrol negativos de nr2b
UY34612A (es) ?procedimiento para la preparación de derivados de isoxazolina azetidina quirales como agentes antiparasitarios?.
BR112016027133A8 (pt) derivados de imidazol como moduladores do receptor de formil peptídeo, composição farmacêutica e uso
UY34408A (es) Nuevos moduladores de trpv3
UY35751A (es) Moduladores negativos de n-arilmetilo sulfonamida de nr2a
EA201500941A1 (ru) Способы и композиции для модуляции гамма-глутамилового цикла
CO7160067A2 (es) Formulaciones de agonistas del receptor de somatostatina
MX2016005227A (es) Polipéptidos de acción prolongada y métodos para su producción y administración.
UA116372C2 (uk) Частинки резинату фенілефрину